These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37525039)

  • 21. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
    Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
    Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
    Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
    FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology.
    Chedid J; Labrador-Garrido A; Zhong S; Gao J; Zhao Y; Perera G; Kim WS; Halliday GM; Dzamko N
    J Biol Chem; 2022 Aug; 298(8):102260. PubMed ID: 35841928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
    Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
    Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease.
    Uehara T; Choong CJ; Nakamori M; Hayakawa H; Nishiyama K; Kasahara Y; Baba K; Nagata T; Yokota T; Tsuda H; Obika S; Mochizuki H
    Sci Rep; 2019 May; 9(1):7567. PubMed ID: 31110191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of the Parkinson's Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32.
    Pavlou MAS; Colombo N; Fuertes-Alvarez S; Nicklas S; Cano LG; Marín MC; Goncalves J; Schwamborn JC
    Mol Neurobiol; 2017 Aug; 54(6):4257-4270. PubMed ID: 27339877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
    Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
    Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
    Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inducible Alpha-Synuclein Expression Affects Human Neural Stem Cells' Behavior.
    Zasso J; Ahmed M; Cutarelli A; Conti L
    Stem Cells Dev; 2018 Jul; 27(14):985-994. PubMed ID: 29669468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of the α-synuclein expression promotes slowing down early neuropathology development in the
    Golomidov IM; Latypova EM; Ryabova EV; Bolshakova OI; Komissarov AE; Sarantseva SV
    J Neurogenet; 2022 Mar; 36(1):1-10. PubMed ID: 35467466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease.
    Xun Z; Sowell RA; Kaufman TC; Clemmer DE
    Mol Cell Proteomics; 2008 Jul; 7(7):1191-203. PubMed ID: 18353766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity.
    Hu D; Sun X; Liao X; Zhang X; Zarabi S; Schimmer A; Hong Y; Ford C; Luo Y; Qi X
    Acta Neuropathol; 2019 Jun; 137(6):939-960. PubMed ID: 30877431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Axonal pathology in hPSC-based models of Parkinson's disease results from loss of Nrf2 transcriptional activity at the Map1b gene locus.
    Czaniecki C; Ryan T; Stykel MG; Drolet J; Heide J; Hallam R; Wood S; Coackley C; Sherriff K; Bailey CDC; Ryan SD
    Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14280-14289. PubMed ID: 31235589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
    Oh Y
    BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genes Implicated in Familial Parkinson's Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage.
    Franco R; Rivas-Santisteban R; Navarro G; Pinna A; Reyes-Resina I
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.